Artivion, Inc.
Artivion, Inc.（AORT）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · AORT · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
62
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Artivion, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
AORT 季度内部人买卖趋势
AORT 内幕交易卖出 · AORT 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · AORT CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
AORT 高管卖出股份 · AORT 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 2, 2026 | SEMEDO ANTHONY B. Director | Other | 6,325 | — | Form 4 |
| Jun 2, 2026 | SEMEDO ANTHONY B. Director | Other | 6,325 | — | Form 4 |
| May 18, 2026 | SEMEDO ANTHONY B. Director | Award | 7,576 | — | Form 4 |
| May 18, 2026 | Salveson Jon W Director | Award | 7,576 | — | Form 4 |
| May 18, 2026 | Hoff Elizabeth A Director | Award | 7,576 | — | Form 4 |
| May 18, 2026 | Burbank Jeffrey H Director | Award | 7,576 | — | Form 4 |
| May 18, 2026 | Bullock James Director | Award | 7,576 | — | Form 4 |
| May 18, 2026 | BEVEVINO DANIEL J Director | Award | 7,576 | — | Form 4 |
| May 18, 2026 | ACKERMAN THOMAS F Director | Award | 7,576 | — | Form 4 |
| May 14, 2026 | Borgstrom Marna P Director | Award | 7,850 | — | Form 4 |
| Mar 2, 2026 | Horton Amy VP, Chief Accounting Officer | Award | 7,475 | — | Form 4 |
| Mar 3, 2026 | Horton Amy VP, Chief Accounting Officer | Sale | 901 | $34K | Form 4 |
| Mar 2, 2026 | Holloway Jean F SVP, General Counsel | Award | 27,795 | — | Form 4 |
| Mar 3, 2026 | Holloway Jean F SVP, General Counsel | Sale | 3,843 | $145K | Form 4 |
| Mar 4, 2026 | Holloway Jean F SVP, General Counsel | Sale | 8,962 | $341K | Form 4 |
| Mar 2, 2026 | Stanton Marshall S. SVP, Clinical & MD Affair | Award | 21,838 | — | Form 4 |
| Mar 3, 2026 | Stanton Marshall S. SVP, Clinical & MD Affair | Sale | 2,149 | $81K | Form 4 |
| Mar 2, 2026 | Davis John E Chief Commercial Officer | Award | 28,845 | — | Form 4 |
| Mar 3, 2026 | Davis John E Chief Commercial Officer | Sale | 4,573 | $173K | Form 4 |
| Mar 2, 2026 | Berry Lance A EVP, COO, CFO & Treasurer | Award | 40,874 | — | Form 4 |
| Mar 3, 2026 | Berry Lance A EVP, COO, CFO & Treasurer | Sale | 6,316 | $239K | Form 4 |
| Mar 2, 2026 | Mackin James P President & CEO | Award | 116,948 | — | Form 4 |
| Mar 3, 2026 | Mackin James P President & CEO | Sale | 17,887 | $676K | Form 4 |
| Mar 2, 2026 | Horton Amy VP, Chief Accounting Officer | Sale | 641 | $24K | Form 4 |
| Mar 2, 2026 | Stanton Marshall S. SVP, Clinical & MD Affair | Sale | 1,513 | $58K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 AORT 内幕交易
AORT 内幕交易
Artivion, Inc.（AORT）内幕交易数据来源于公司内部人（包括Holloway Jean F (SVP, General Counsel), Stanton Marshall S. (SVP, Clinical & MD Affair), Davis John E (Chief Commercial Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。AORT内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Artivion, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
AORT 内幕交易 · 5个问题Artivion, Inc.（AORT）的内部人包括高管和董事，如Holloway Jean F (SVP, General Counsel), Stanton Marshall S. (SVP, Clinical & MD Affair), Davis John E (Chief Commercial Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026